Merck Serono, the biopharmaceutical division of pharmaceutical conglomerate Merck, has made an investment in the series A round for US-based reproductive health company Auxogyn through its corporate venturing fund, Merck Serono Ventures. The round closed on Thursday, with Auxogyn having raised $20m. Merck was joined in the round by TPG Biotech, the life sciences investment…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
